openPR Logo
Press release

Gemigliptin Market Growth: Anticipated to Exceed USD 2.65 Billion by 2031.

12-23-2024 08:01 AM CET | Health & Medicine

Press release from: Insightace Analytic Pvt Ltd.

Gemigliptin Market

Gemigliptin Market

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And Industry Analysis 2031"

The global Gemigliptin Market is estimated to reach over USD 2.65 billion by 2031, exhibiting a CAGR of 5.5% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2031

Gemigliptin is an oral diabetes medicine that belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is used to treat type 2 diabetes, a chronic metabolic condition marked by insulin resistance and high blood sugar levels. Gemigliptin works by inhibiting the enzyme DPP-4, which is in charge of the breakdown of incretin hormones, which regulate blood glucose levels.

Gemigliptin enhances the levels of these hormones by blocking DPP-4, resulting in improved insulin secretion and decreased glucose synthesis by the liver. Due the rising incidence of diabetes worldwide and the increasing acceptance of efficient oral antidiabetic medications, the global Gemigliptin market has been steadily growing. Pharmaceutical companies continue investing in R&D to improve existing pharmaceuticals and discover novel treatments. This continuous innovation could lead to the release of newer and more advanced DPP-4 inhibitors, thereby growing the market. Gemigliptin is becoming more popular as a safer and more convenient diabetes treatment choice.

List of Prominent Players in the Gemigliptin Market:
• LG Chem
• Hanmi Pharmaceutical Co., Ltd.
• Boryung Pharmaceutical Co., Ltd.
• Novartis AG
• EirGenix, Inc.
• Biocon Limited
• G.L. Pharma GmbH
• Daewoong Pharmaceutical Co., Ltd.
• Sandoz International GmbH
• Boryung Pharmaceutical Co., Ltd.
• VHB Life Sciences Limited
• HanAll Biopharma
• Taiba Healthcare
• Huons Co., Ltd.
• Dong-A ST Co., Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:
Drivers-
Diabetes is becoming more common worldwide at an alarming rate, affecting millions of people. Diabetes is becoming a significant public health concern, and there is an increasing demand for effective and safe antidiabetic medications like Gemigliptin to control the condition and improve patient outcomes. Furthermore, oral antidiabetic drugs are gradually replacing insulin injections due to their comfort and ease of administration. Gemigliptin is an oral antidiabetic medicine favored by patients who are not insulin-dependent, contributing to its market growth.

Challenges:
Gemigliptin faces significant competition from other types of diabetes drugs, such as metformin, sulfonylureas, and SGLT-2 inhibitors. Established pharmaceuticals with a lengthy history of usage and proven performance may hinder the market penetration of newer therapies like Gemigliptin. Patents on Gemigliptin and other DPP-4 inhibitors may expire, allowing generic copies to enter the market. This can lead to pricing challenges and limited revenue possibilities for branded Gemigliptin medicines. In addition, As with any medicine, safety issues might influence patient and physician opinions of Gemigliptin. Although the safety profile of Gemigliptin is generally well-established, continued monitoring and any safety alerts may limit its uptake and use.

Regional Trends:
The North America Gemigliptin Market is expected to report a major market share and is projected to grow at a high CAGR shortly. Diabetes, particularly type 2 diabetes, is a significant driver of the Gemigliptin market in North America. Diabetes has become more prevalent in the region due to factors such as sedentary lifestyles, bad diets, and obesity. Because of North America's well-developed healthcare infrastructure, drugs such as Gemigliptin are widely available. Healthcare providers have the resources necessary to diagnose, treat, and control diabetes properly. Diabetes prevalence, particularly type 2 diabetes, has risen dramatically in Asia. Changes have aided this rise in lifestyle, urbanization, and food preferences. The Asia Pacific area has a sizable generics market, and the advent of generic versions of Gemigliptin or other DPP-4 inhibitors could have an impact on market dynamics.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2031

Recent Developments:
• In March 2023, Sanofi introduced a new fixed-dose combination medication, including gemigliptin and saxagliptin (Jentadueto XR), in the United States. This medicine is indicated for treating individuals with type 2 diabetes mellitus who are not effectively controlled with diet and exercise alone or with other diabetes drugs.

Segmentation of Gemigliptin Market-
By Type of Drug-
• Gemigliptin Monotherapy
• Gemigliptin Combination Therapy)
By Dosage Form-
• Gemigliptin Tablets
• Gemigliptin Injectable
By Distribution Channel-
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End-User-
• Hospitals
• Clinics and Outpatient Facilities
• Homecare Settings
By Application-
• Type 2 diabetes
• Prediabetes
By Patient Demographics-
• Adult Population
• Geriatric Population
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2031

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gemigliptin Market Growth: Anticipated to Exceed USD 2.65 Billion by 2031. here

News-ID: 3795121 • Views:

More Releases from Insightace Analytic Pvt Ltd.

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market to Grow at 5.3% CAGR Amid Rising Awareness of PCOS and PMS
Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market to Grow at 5 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market- (By Product Type (Combined Nutritional Supplements, Single Nutritional Supplements), By Type Indication (Perimenopause, PMS), By Formulation (Capsules/Tablets, Powder, Softgels, Other), By Sales Channel (Pharmacies/Drug Stores, Online Sales Channel, Direct Sales Channel, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research
Cell and Gene Therapy CRO Market Forecast Shows Robust Growth Across North America, Europe, and Asia-Pacific
Cell and Gene Therapy CRO Market Forecast Shows Robust Growth Across North Ameri …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy CRO Market- (By Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), By Type of Genetic Modification (Ex vivo and In vivo), By Stage of Development (Discovery, Preclinical, and Clinical)), By Therapeutic Area, By End-user, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by
Bioseparation Systems Market Top Companies Study - GE Healthcare Life Sciences, Pall Corporation, 3M Company, Waters Corporation.
Bioseparation Systems Market Top Companies Study - GE Healthcare Life Sciences, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Bioseparation Systems Market- (By Type (Centrifugation Technology, Cell Disruption Technology, Chromatography Technique, Extraction Technique, Filtration Technologies and Membrane-based Bioseparation and Precipitation), Application (Food, Life Sciences, Pharmaceutical and Biopharmaceutical)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Bioseparation Systems Market is valued at US$
Medical Nutrition Market Key Players Analysis - Abbott Laboratories; Pfizer Inc.; Bayer AG; Nestle S.A.; GlaxoSmithKline plc.
Medical Nutrition Market Key Players Analysis - Abbott Laboratories; Pfizer Inc. …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Medical Nutrition Market Size, Share & Trends Analysis Report By Nutrition Type (Proteins, Carbohydrates, Multivitamins & Antioxidants, Amino Acids, Fibers, Minerals), By Indication (Diabetes, Cancer, Gastrointestinal Diseases, Metabolic Syndromes), By Patient Type (Infants, Adults, And Geriatric Populations), Indication (Diabetes, Cancer, Gastrointestinal Diseases, Metabolic Syndromes), End-User (Home Care Settings, Long-Term Care Facilities, And Ambulatory Surgical

All 5 Releases


More Releases for Gemigliptin

Gemigliptin Market Current Scenario with Future Aspect Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And
Gemigliptin Market Revenue Report with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And
Gemigliptin Market Study Analysis with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And
Gemigliptin Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And
Gemigliptin Market Research Report 2023 | InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And
Global Gemigliptin Market Size,Share,Development Overview,2023-2028|Sanofi, LG C …
Los Angeles, United States, - The report on the global Glass Bottle for Vaccine Use market is comprehensively prepared with a main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that players could improve their sales and growth in the Global Glass Bottle for Vaccine Use Market. It offers a detailed analysis of